Compares zanzalintinib with everolimus in people with advanced neuroendocrine tumors
Tests zanzalintinib against everolimus in adults with previously treated neuroendocrine tumors.
Plain-language title generated from the registry record
Registry title: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Key facts
- Where
- Albuquerque, Bethesda, Beverly Hills, Birmingham, Boston, Buffalo, Chapel Hill, Charlottesville, Cleveland, Columbus, Dallas, Detroit, Durham, Fairfax, Fargo, Grand Rapids, Jacksonville, Knoxville, Lexington, Los Angeles, Metairie, Milwaukee, Nashville, New York, Omaha, Orlando, Palo Alto, Philadelphia, Phoenix, Pittsburgh, Portland, Rochester, Salt Lake City, Santa Monica, Seattle, St Louis, Tampa, Tucson, Vallejo, and Washington D.C., United StatesSee the 41 sites
- Phase
- Phase 2/3
Where in United States
- University of New Mexico Comprehensive Cancer CenterAlbuquerque, United StatesTaking people
- National Institute Of HealthBethesda, United StatesTaking people
- Cedars-Sinai Medical CenterBeverly Hills, United StatesTaking people
- The University of Alabama at BirminghamBirmingham, United StatesTaking people
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
- Roswell Park Cancer InstituteBuffalo, United StatesTaking people
- University of North Carolina at Chapel HillChapel Hill, United StatesTaking people
- University of VirginiaCharlottesville, United StatesTaking people
- University Hospitals Cleveland Medical Center*Cleveland, United StatesTaking people
- The Ohio State University Comprehensive Cancer CenterColumbus, United StatesTaking people
- Texas Oncology - Baylor Charles A. Sammons Cancer CenterDallas, United StatesTaking people
- Henry Ford Cancer- DetroitDetroit, United StatesTaking people
- Duke University Medical CenterDurham, United StatesTaking people
- Virginia Cancer Specialists - Fairfax OfficeFairfax, United StatesTaking people
- Sanford Roger Maris Cancer CenterFargo, United StatesTaking people
- The Cancer and Hematology CentersGrand Rapids, United StatesTaking people
- Mayo Clinic FloridaJacksonville, United StatesTaking people
- University of Tennessee Medical CenterKnoxville, United StatesTaking people
- University of Kentucky/Markey Cancer CenterLexington, United StatesTaking people
- Norris Comprehensive Cancer CenterLos Angeles, United StatesTaking people
- East Jefferson General HospitalMetairie, United StatesTaking people
- Froedtert Hospital and the Medical College of WisconsinMilwaukee, United StatesTaking people
- Henry-Joyce Cancer ClinicNashville, United StatesTaking people
- Icahan School of Medicine at Mount SinaiNew York, United StatesTaking people
- University of Nebraska Medical CenterOmaha, United StatesTaking people
- AdventHealth OrlandoOrlando, United StatesTaking people
- Stanford Cancer CenterPalo Alto, United StatesTaking people
- University of PennsylvaniaPhiladelphia, United StatesTaking people
- Mayo Clinic HospitalPhoenix, United StatesTaking people
- University of Pittsburgh Medical Center (UPMC) - Hillman Cancer CenterPittsburgh, United StatesTaking people
- Oregon Health and Science UniversityPortland, United StatesTaking people
- Mayo ClinicRochester, United StatesTaking people
- University of Rochester Medical CenterRochester, United StatesTaking people
- Huntsman Cancer Institute/University of UtahSalt Lake City, United StatesTaking people
- UCLA Health - Santa Monica Cancer CareSanta Monica, United StatesTaking people
- Fred Hutchinson Cancer CenterSeattle, United StatesTaking people
- Siteman Cancer CenterSt Louis, United StatesTaking people
- Moffitt Cancer CenterTampa, United StatesTaking people
- The University of Arizona Cancer CenterTucson, United StatesTaking people
- Kaiser Permanente Medical CenterVallejo, United StatesTaking people
- Georgetown UniversityWashington D.C., United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Exelixis
- Trial code
- NCT06943755EU 2025-521043-20-00
- Record updated
- 30 October 2026
- Original description
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.Read full original descriptionShow less
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Inclusion: Histologically confirmed, locally advanced/unresectable or metastatic, well-differentiated Grade 1, 2, or 3 NETs of pancreatic origin or extra-pancreatic origin; Allowed prior lines of therapy, based on the site of NET and functional status; Documented radiographic disease progression per RECIST 1.1, as assessed by the Investigator based on imaging assessments (computed tomography [CT] or magnetic resonance imaging [MRI]) within 12 months before randomization; Measurable disease according to RECIST 1.1 as determined by the Investigator; Archival tumor tissue is required, if available. If archival tumor tissue is not available, a fresh biopsy may be submitted if it can be safely and feasibly obtained. Every attempt should be made to provide tumor tissue.
Exclusion: Prior treatment with a vascular endothelial growth factor receptor (VEGFR) -targeting tyrosine kinase inhibitor or a mammalian target of rapamycin (mTOR) inhibitor; Systemic chemotherapy and any liver-directed or other ablative therapy within 4 weeks before randomization; Systemic radionuclide therapy within 6 weeks before randomization; Radiation therapy for bone metastases within 2 weeks, any other radiation therapy, except as indicated above, within 4 weeks before randomization; Note: Other protocol defined Inclusion/Exclusion criteria may apply; Histologically confirmed neuroendocrine carcinomas (including small cell lung cancer), medullary thyroid cancer, pheochromocytoma, paraganglioma, Merkel cell carcinoma, and mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN).